In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $3.50 price target, …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $30 price target. The report comes ahead of the FDA’s long-anticipated …
In a report issued today, H.C.
In a research report released today, Cantor Fitzgerald analyst Youssef Squali reiterated a Buy rating on Yahoo (YHOO) with a $39 price target, following Alibaba’s 2Q:CY14 financial results, which were better than …
In a research note released this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a $24 …
Salesforce.com (NYSE: CRM) reported what’s consider to be a very clean quarter—revenue was $31 million above consensus, non-GAAP EPS a penny better, and …
In a research report published today, Wedbush analyst Michael Pachter maintained an Outperform rating on GameStop (NYSE:GME) with a $60 price target, following the company’s second-quarter results that beat Street …
Galena Biopharma (GALE) announced today the resignation of CEO Mark Ahn and the instillation of COO, Mark Schwartz as its new CEO. In reaction …
JA Solar Holdings (JASO) posted a slight second-quarter miss, issued a weaker-than-expected third-quarter shipment guide, and lowered its GM outlook. As a result, estimates are likely …
Amicus Therapeutics (FOLD) today announced robust 18-month data from the migalastat monotherapy Study 012 in Fabry patients with amenable mutations. Migalastat met the …
